Following the exploitation of BCR/ABL kinase inhibition in chronic myeloid leukaemia, efforts have been made to explore PP2A phosphatase reactivation/inhibition in anti-tumour therapy. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.